Alpha1-antichymotrypsin-PSA (ACT-PSA): A useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4767-4770

  Reiter, W ^a   Stieber, P ^a   Schmeller, N ^a   Nagel, D ^a   Fateh Moghadam, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alpha1 antichymotrypsin prostate specific antigen (ACT PSA); Benign hyperplasia of the prostate; Prostate cancer; Ratio Q = ACT PSA:t PSA; Total prostate specific antigen (t PSA)

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ALPHA 1-ANTICHYMOTRYPSIN; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0031408487     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R: Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166-3170, 1986.
2. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu T: Prostate antigen: a new potential marker for prostatic cancer. Prostate 2: 89-96, 1981.
3. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
4. Fateh-Moghadam A, Stieber P: Sensible use of tumour markers. 2nd edition Jurgen Hartmann Verlag GmbH, Marloffstein-Rathsberg, Germany, 1993.
5. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tukkanen K, Alfthan O: A complex between prostate-specific antigen and alpha1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
6. Lilja H, Christensson A, Dahlen U, Matikainen M-T, Nilsson O, Pettersson K, Ldvgren T: Prostate-specific antigen in serum occurs predominantly in compex wilh alpha1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
7. Catolona WJ, Smith DS: Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer 74: 1516-1518, 1994.
8. Partin AW, Kelly CA, Subong ENP, Walsh PC, Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Norton KC, Mc Cormack R: Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with lotal PSA levels between 4 and 10 ng/ml. J Urol 153: 295A, 1995.
9. Prestigiacomo AF, Stamey TA: Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 55 (Suppl. 221): 323-324, 1995.
10. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274(18): 12141220, 1995.
11. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41(8): 11151120, 1995.
12. Van Dalen A: Quality control and standardization of tumour marker tests. Tumor Biol 14: 131-135, 1993.
13. Kojima M, Babaian RJ: Algorithmus for early deteetion of prostate eaneer. Current state of the "art". Cancer 75(Suppl 7): 1860-1868, 1995.
14. Oesterling JE: Prostate specific antigen: its role in the diagnosis and staging of prostate cancer. Cancer 75(Suppl 7): 1795-1804, 1995.
15. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan PC, de Kernion JB, Ratliff TL, Kavousi LR, Dalkin BL, Walters WB, Mac Farlane MT, Southwich PC: Comparison of digital examination and serum prostate specific antigen in the early deteetion of prostate eaneer: results of a multicenter clinical trial of 6.630 men. J Urol 151: 1283-1290, 1994.
16. Wu JT, Wilson L, Zhang P, Meikle AW, Stephenson R: Correlation of serum concentration of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 9: 15-24, 1995.
17. Wu JT: Assay for prostate specific antigen (PSA) problems and possible solutions. J Clin Lab Anal 8: 51-62, 1994.
18. Wilson L, Stephenson R, Meikle W, Wu J: Measurement of serum PSA-ACT complex in patients with BPH and prostate cancer: feasibility and advantages. Clin Chem 40: 1004-1010, 1994.
19. Densel M, Rittenhouse H, Cazares L, Wolfert R: Detection of prostate specific antigen complexed to alphal-antichymotrypsin (PSA/ACT) and uncomplexed PSA in serum from patients with benign prostate hypertrophy (BPH) and prostate cancer (PCA) using dual monoclonal assays. J Urol 149: 333A, 1993.
20. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG: Multiple forms of prostate-specific antigen in serum measured differently in equimolar-and skewedresponse assays. Clin Chem 41: 125-126, 1995.
21. Schambeck, C.M, Schmeller, N, Stieber, P, Jansen, H,M, Pahl, H, Schneider, W, Fateh-Moghadam, A: Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen in prostate cancer. Urology 46: 195-199, 1995.